The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Final results of the ACTS-CC 02 trial: A randomized phase III trial of S-1/oxaliplatin (SOX) versus UFT/leucovorin as adjuvant chemotherapy for high-risk stage III colon cancer.
 
Naohiro Tomita
Honoraria - Chugai Pharma; Taiho Pharmaceutical
Research Funding - Chugai Pharma (Inst); Lilly Japan (Inst); Sysmex (Inst); Taiho Pharmaceutical (Inst)
 
Shin Sasaki
No Relationships to Disclose
 
Tetsuya Kusumoto
No Relationships to Disclose
 
Jun Watanabe
Honoraria - Johnson & Johnson; Medtronic
Speakers' Bureau - Johnson & Johnson; Medtronic
 
Yoshiyuki Sakamoto
No Relationships to Disclose
 
Kazuhiro Yoshida
Honoraria - Asahi Kasei; AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Covidien; Daiichi Sankyo; Denka Co., Ltd; EA Pharma; Eisai; Johnson & Johnson; Lilly Japan; Merck Serono; MSD K.K; Nippon Kayaku; Novartis; Olympus; Ono Pharmaceutical; Otsuka; Pfizer; Sanofi; Sanwa Kagaku Kenkyusho; SBI Pharmaceuticals; Taiho Pharmaceutical; Takeda; Teijin Pharma; TERUMO; Tsumura & Co.; Yakult Honsha
Research Funding - Abbott (Inst); Abbvie (Inst); Asahi Kasei (Inst); Astellas Pharma (Inst); Biogen (Inst); Celgene (Inst); Chugai Pharma (Inst); Covidien (Inst); Daiichi Sankyo (Inst); Eisai (Inst); GlaxoSmithKline K.K. (Inst); Johnson & Johnson (Inst); Kaken Pharmaceutical (Inst); KCI (Inst); Koninklijke philips (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Meiji Seika Kaisha (Inst); Merck Serono (Inst); MSD K.K (Inst); Nippon Kayaku (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Otsuka (Inst); Sanofi/Aventis (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Toray Industries (Inst); Tsumura & Co. (Inst); Yakult Honsha (Inst)
 
Atsuyuki Maeda
No Relationships to Disclose
 
Jin Teshima
No Relationships to Disclose
 
Mitsuru Yokota
No Relationships to Disclose
 
Chihiro Tanaka
No Relationships to Disclose
 
Junichiro Yamauchi
No Relationships to Disclose
 
Hiroyuki Uetake
Speakers' Bureau - Bayer; Chugai Pharma; Daiichi Sankyo; Taiho Pharmaceutical; Takeda
 
Michio Itabashi
Research Funding - Astellas Pharma (Inst); Chugai Pharma (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Keiichi Takahashi
Honoraria - Chugai Pharma; Lilly Japan; Taiho Pharmaceutical
 
Hideo Baba
Honoraria - Taiho Pharmaceutical
Research Funding - Chugai Pharma (Inst); MSD K.K (Inst); Ono Pharmaceutical (Inst); Shin Nippon Biomedical (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst)
 
Kenjiro Kotake
No Relationships to Disclose
 
Narikazu Boku
Honoraria - Bristol-Myers Squibb Japan; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Ono Pharmaceutical (Inst); Takeda (Inst)
 
Keisuke Aiba
No Relationships to Disclose
 
Satoshi Morita
Honoraria - AstraZeneca Japan; Bristol-Myers Squibb; Chugai Pharma; Eisai; Lilly; Merck Sharp & Dohme; Nippon Boehringer Ingelheim; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Research Funding - Nippon Boehringer Ingelheim (Inst)
 
Kenichi Sugihara
Honoraria - Taiho Pharmaceutical; Taiho Pharmaceutical
Research Funding - Chugai Pharma (Inst); Taiho Pharmaceutical (Inst)